Table 5 Hazard ratios of each irAE to overall survival by primary disease.

From: Clinical outcomes of endocrine and other disorders induced by immune checkpoint inhibitors in Japanese patients

Primary disease

Non-irAE

E-irAE

O-irAE

EO-irAE

ME-irAE

Non-small cell lung cancer (n = 179) (%)

1.000

0.515 (0.325–0.795)

0.766 (0.517–1.125)

0.551 (0.339–0.872)

0.340 (0.081–0.958)

Gastrointestinal tumors (n = 144) (%)

1.000

0.695 (0.440–1.069)

0.636 (0.379–1.023)

0.757 (0.349–1.452)

0.539 (0.030–2.467)

Hepatocellular carcinoma (n = 44) (%)

1.000

0.773 (0.303–2.028)

0.847 (0.292–2.425)

1.276 (0.478–3.390)

1.193 (0.176–5.008)

Otolaryngological tumors (n = 43) (%)

1.000

0.421 (0.102–1.305)

0.340 (0.077–1.043)

0.342 (0.104–0.925)

-

Urothelial cancer (n = 42) (%)

1.000

0.716 (0.259–1.822)

1.526 (0.318–5.374)

0.689 (0.103–2.673)

0.287 (0.013–2.332)

Malignant melanoma (n = 35) (%)

1.000

0.991 (0.323–2.824)

0.937 (0.327–2.665)

1.036 (0.133–8.473)

0.991 (0.323–2.824)

Renal cell cancer (n = 27) (%)

1.000

0.017 (0.001–0.200)

0.054 (0.004 − 0.001)

0.158 (0.028–0.888)

0.352 (0.056–1.776)

Small cell lung cancer (n = 23)

1.000

1.181 (0.300–4.058)

2.199 (0.607–7.521)

-

0.041 (0.002–0.535)

  1. Data are presented as median (95%CI), irAE; immune-related adverse events, E-irAE; endocrine-related irAE, O-irAE; other irAE, EO-irAE; endocrine-related and other irAE, ME-irAE; multiple endocrine-related irAE. COX proportional hazard ratios based on multivariate analysis adjusted for age, sex, history of chemotherapy, history of radiotherapy, and immune checkpoint inhibitors administered.
Back to article page